Celldex Therapeutics (NASDAQ:CLDX) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $64.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 102.21% from the stock’s current price.

Several other brokerages have also recently commented on CLDX. Canaccord Genuity Group dropped their price target on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Wells Fargo & Company boosted their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. UBS Group boosted their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Morgan Stanley boosted their price target on shares of Celldex Therapeutics from $50.00 to $57.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 23rd. Finally, Stifel Nicolaus set a $68.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $61.92.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX traded down $0.53 during midday trading on Friday, reaching $31.65. 2,404,662 shares of the company traded hands, compared to its average volume of 1,064,734. Celldex Therapeutics has a 52 week low of $22.10 and a 52 week high of $45.14. The stock has a 50-day moving average price of $38.38 and a 200 day moving average price of $34.89. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -7.28 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.74 million. As a group, analysts expect that Celldex Therapeutics will post -4.17 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nykredit A S acquired a new stake in Celldex Therapeutics during the 2nd quarter worth about $67,000. Diversified Trust Co acquired a new stake in Celldex Therapeutics during the 1st quarter worth about $223,000. Walleye Capital LLC acquired a new stake in Celldex Therapeutics during the 1st quarter worth about $258,000. Amundi acquired a new stake in Celldex Therapeutics during the 1st quarter worth about $297,000. Finally, Glenmede Trust Co. NA acquired a new stake in Celldex Therapeutics during the 1st quarter worth about $357,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.